This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Brain injury in preterm infants, as demonstrated with neonatal MRI, is associated with adverse neurodevelopmental outcomes in cognitive, language, motor, educational, behavioral, and social domains.1 Such brain injury is heterogeneous, is rarely localized, and evolves over time. White matter injury (WMI) in preterm infants is by far the most frequent brain injury, and occurs in over 70% of preterm infants born before 31 weeks of gestation.2 WMI found in the preterm brain includes cystic lesions, focal small lesions with high signal intensity (best seen on T1-weighted images), diffuse excessive high signal intensity (DEHSI), and loss of white matter volume. Although classic cystic periventricular leukomalacia is becoming rarer, DEHSI is seen often, and is obvious at term-equivalent age (TEA). Its specific relevance is open for debate, with poor predictive value for 2-year outcomes.3 However, qualitative MRI analysis assessing loss of substance (white matter atrophy, ventricular dilation, and associated corpus callosum thinning) at TEA is able to predict 2-year outcomes.4 In this era of active research for new neuroprotective therapies in the neonatal period, robust comprehensive approaches are warranted not just to predict the consequences of injury, but also to identify newborns who could benefit from future targeted neuroprotective therapies. So far, only a handful of systematic qualitative or quantitative MRI approaches have been evaluated or used to assess therapeutic efficiency.5,6
Footnotes
Go to Neurology.org for full disclosures. Funding information and disclosures deemed relevant by the authors, if any, are provided at the end of the editorial.
See page 614
- © 2017 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
